| Vol. 13.32 – 27 August, 2021 |
| |
|
|
| Researchers compared the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C. [Cancer Cell] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators analyzed tissue-resident memory T cell (TRM) heterogeneity between organs and found that the different environments in which these cells differentiate dictated TRM cell function, durability and malleability. [Nature Immunology] |
|
|
|
| By reinstating Foxp3 protein expression and suppressor function in cells expressing a reversible Foxp3 null allele in severely diseased mice, researchers found that the resulting single pool of rescued Treg cells normalized immune activation, quelled severe tissue inflammation, reversed fatal autoimmune disease and provided long-term protection against them. [Nature Immunology] |
|
|
|
| Using an immunocompetent mouse model expressing a humanized CD3ε chain and bispecific T cell engager (BiTE) molecules directed against mouse CD19, mouse CLDN18.2, or human EPCAM antigens, researchers investigated the pharmacokinetic and pharmacodynamic parameters and immune correlates associated with BiTE efficacy across multiple syngeneic solid-tumor models. [Science Translational Medicine] |
|
|
|
| Investigators developed new transgenic mice to profile pulmonary GM-CSF expression, which they detected in both immune cells, including group 2 innate lymphoid cells and γδ T cells, as well as AT2s. [Journal of Experimental Medicine] |
|
|
|
| The authors visualized central nervous system inflammatory processes in models of multiple sclerosis (MS) live in vivo and in MS brains and discovered that central nervous system-infiltrating T helper 17 cells form prolonged stable contact with oligodendrocytes. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers showed that leucine-rich repeat kinase 2 (LRRK2) expression was clearly reduced in mammalian fibrotic lungs, and LRRK2-deficient mice exhibited aggravated bleomycin-induced pulmonary fibrosis. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors showed that interleukin-13 packaged in extra-large-pore mesoporous silica nanoparticles was protected from degradation and directs the alternative activation of macrophages both in vitro and in vivo. [ACS Biomaterials Science & Engineering] |
|
|
|
| Investigators established cytotoxicity model of chicken spleen lymphocytes by HgCl2 exposure, the mRNA expression levels of 25 selenoproteins in spleen lymphocytes were analyzed by real-time quantitative PCR, and the gene expression pattern of selenoproteins was revealed by principal component analysis. [Biological Trace Element Research] |
| |
|
|
|
| Scientists discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors discuss the importance of oncolytic viruses-based combination therapies in optimizing antiviral and antitumor innate immune responses stimulated by virotherapy toward tumor eradication, and how these processes vary depending on the tumor and oncolytic viruses in question. [Cancer Gene Therapy] |
|
|
|
|
| Bolt Biotherapeutics, Inc. and Innovent Biologics, Inc. announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate candidates. [Bolt Biotherapeutics, Inc.] |
|
|
|
| ImmunoBrain Checkpoint, Inc. announced that the National Institute on Aging (NIA) of the US National Institutes of Health has awarded the company a grant totaling $5 million over three years to support a first-in-human clinical study of IBC-Ab002, for the treatment of Alzheimer’s disease. [ImmunoBrain Checkpoint, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| Bolt Biotherapeutics, Inc. and Innovent Biologics, Inc. announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate candidates. [Bolt Biotherapeutics, Inc.] |
|
|
|
|
| October 13 – 14, 2021 London, England, United Kingdom |
|
|
|
|
|
| University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| Epitopea – Cambridge, England, United Kingdom |
|
|
|
| Dana-Farber Cancer Institute- Boston, Massachusetts, United States |
|
|
|
| Medical College of Georgia, Augusta University – Augusta, Georgia, United States |
|
|
|
|